Regencell Bioscience Leads Pharma Stocks in Year-to-Date Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Source: SeekingAlpha
S&P Healthcare Index Performance: The S&P healthcare index (XLV) achieved a year-to-date increase of 12.2% by mid-December 2025, ranking as the sixth-highest performing sector among the S&P 500 indexes.
Top Pharmaceutical Stocks: Regencell Bioscience (RGC) led the pharmaceutical sector with an extraordinary YTD performance of +15,138.46%, followed by Terns Pharmaceuticals (TERN) and Nuvation Bio (NUVB), which both received strong buy ratings.
Notable Stock Ratings: Nuvation Bio (NUVB) and Liquidia (LQDA) were highlighted for their strong buy ratings of 4.99 and 4.90, respectively, indicating strong investment potential.
Healthcare ETFs: Various healthcare ETFs, including XLV, VHT, and IHI, were mentioned as options for investors looking to gain exposure to the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: LKQ faces a class action lawsuit for the period from February 27, 2023, to July 23, 2025, alleging that executives failed to disclose significant risks regarding customer losses and market share erosion, misleading investors and negatively impacting the company's reputation and stock price.
- Regencell Bioscience Lawsuit: During the class period from October 28, 2024, to October 31, 2025, Regencell is accused of not disclosing risks of market manipulation and financial exposure, which could lead to legal and reputational harm, increasing investor anxiety.
- Globant Lawsuit: Globant is facing a class action for the period from February 15, 2024, to August 14, 2025, due to failure to disclose decreasing demand in Latin America and wage freezes, severely undermining investor confidence in the company's prospects.
- Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of the deadlines on June 22 and 23, 2026, encouraging them to participate in the lawsuits to protect their rights.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will be ineligible for compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate in the litigation.
- Legal Risk Disclosure: The lawsuit alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks, and the revelation of this information could lead to further declines in the company's stock price, impacting investor confidence.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases, prompting investors to carefully select legal counsel to protect their rights.
See More
Regencell Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal exposure for the company.
- Allegations of False Statements: The complaint alleges that throughout the class period, Regencell made materially false and misleading statements, failing to disclose vulnerabilities to market manipulation, which exposed investors to substantial financial risks.
- Increased Regulatory Risks: The lawsuit highlights that the volatility in Regencell's stock could lead to heightened regulatory scrutiny and enforcement actions, potentially resulting in significant legal, financial, and reputational harm to the company.
- Investor Representation Assurance: Bronstein, Gewirtz & Grossman LLC offers legal representation on a contingency fee basis, ensuring that investors only pay for legal expenses if the lawsuit is successful, thereby safeguarding investor rights in this legal action.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will be ineligible for compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to seek compensation through litigation.
- Legal Risk Disclosure: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and regulatory scrutiny, which could lead to significant financial losses, highlighting the urgent need for corporate transparency and compliance.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovered hundreds of millions for investors, demonstrating its expertise and resource advantages in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Regencell Bioscience Lawsuit: During the period from October 2024 to October 2025, Regencell is accused of failing to disclose market manipulation risks, exposing investors to significant financial risks, which could lead to regulatory scrutiny and impact the company's reputation and operations.
- SES AI Business Prospects Controversy: SES AI is alleged to have overstated its business prospects from January 2025 to March 2026, with logistics constraints affecting Q4 2025 revenues, raising doubts about its growth prospects for 2026 and potentially undermining investor confidence.
- FS KKR Capital Restructuring Issues: FS KKR is accused of exaggerating the effectiveness of its portfolio restructuring efforts from May 2024 to February 2026, which may lead investors to misunderstand the company's financial health and affect its market performance.
- Graphic Packaging Operational Challenges: From February 2025 to February 2026, Graphic Packaging is alleged to have failed to disclose significant inventory management issues and reduced demand, resulting in unreliable financial guidance that could negatively impact the company's future performance.
See More
Regencell Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting concerns over potential legal risks and financial losses for investors.
- Allegations of False Statements: The complaint alleges that Regencell made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks and indicated serious deficiencies in corporate governance and compliance policies.
- Risk of Legal Consequences: The heightened scrutiny from regulatory and governmental bodies could lead to substantial legal, financial, and reputational harm for investors, further exacerbating market distrust in Regencell and negatively impacting its stock performance.
- Investor Rights Protection: Investors have until June 23, 2026, to request lead plaintiff status, with the law firm promising to charge fees only upon successful recovery, ensuring that investors' rights are protected throughout the legal process.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: LKQ faces a class action lawsuit for the period from February 27, 2023, to July 23, 2025, alleging that executives failed to disclose significant risks regarding customer losses and market share erosion, misleading investors and negatively impacting the company's reputation and stock price.
- Regencell Bioscience Lawsuit: During the class period from October 28, 2024, to October 31, 2025, Regencell is accused of not disclosing risks of market manipulation and financial exposure, which could lead to legal and reputational harm, increasing investor anxiety.
- Globant Lawsuit: Globant is facing a class action for the period from February 15, 2024, to August 14, 2025, due to failure to disclose decreasing demand in Latin America and wage freezes, severely undermining investor confidence in the company's prospects.
- Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of the deadlines on June 22 and 23, 2026, encouraging them to participate in the lawsuits to protect their rights.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will be ineligible for compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate in the litigation.
- Legal Risk Disclosure: The lawsuit alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks, and the revelation of this information could lead to further declines in the company's stock price, impacting investor confidence.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases, prompting investors to carefully select legal counsel to protect their rights.
See More
Regencell Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal exposure for the company.
- Allegations of False Statements: The complaint alleges that throughout the class period, Regencell made materially false and misleading statements, failing to disclose vulnerabilities to market manipulation, which exposed investors to substantial financial risks.
- Increased Regulatory Risks: The lawsuit highlights that the volatility in Regencell's stock could lead to heightened regulatory scrutiny and enforcement actions, potentially resulting in significant legal, financial, and reputational harm to the company.
- Investor Representation Assurance: Bronstein, Gewirtz & Grossman LLC offers legal representation on a contingency fee basis, ensuring that investors only pay for legal expenses if the lawsuit is successful, thereby safeguarding investor rights in this legal action.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will be ineligible for compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to seek compensation through litigation.
- Legal Risk Disclosure: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and regulatory scrutiny, which could lead to significant financial losses, highlighting the urgent need for corporate transparency and compliance.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovered hundreds of millions for investors, demonstrating its expertise and resource advantages in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Regencell Bioscience Lawsuit: During the period from October 2024 to October 2025, Regencell is accused of failing to disclose market manipulation risks, exposing investors to significant financial risks, which could lead to regulatory scrutiny and impact the company's reputation and operations.
- SES AI Business Prospects Controversy: SES AI is alleged to have overstated its business prospects from January 2025 to March 2026, with logistics constraints affecting Q4 2025 revenues, raising doubts about its growth prospects for 2026 and potentially undermining investor confidence.
- FS KKR Capital Restructuring Issues: FS KKR is accused of exaggerating the effectiveness of its portfolio restructuring efforts from May 2024 to February 2026, which may lead investors to misunderstand the company's financial health and affect its market performance.
- Graphic Packaging Operational Challenges: From February 2025 to February 2026, Graphic Packaging is alleged to have failed to disclose significant inventory management issues and reduced demand, resulting in unreliable financial guidance that could negatively impact the company's future performance.
See More
Regencell Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting concerns over potential legal risks and financial losses for investors.
- Allegations of False Statements: The complaint alleges that Regencell made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks and indicated serious deficiencies in corporate governance and compliance policies.
- Risk of Legal Consequences: The heightened scrutiny from regulatory and governmental bodies could lead to substantial legal, financial, and reputational harm for investors, further exacerbating market distrust in Regencell and negatively impacting its stock performance.
- Investor Rights Protection: Investors have until June 23, 2026, to request lead plaintiff status, with the law firm promising to charge fees only upon successful recovery, ensuring that investors' rights are protected throughout the legal process.
See More
